Date: 2017-03-06
Type of information: Exercise of an option agreement
Compound: SIMPLE Antibody™ platform, ARGX-116
Company: Argen-X (Belgium) Staten Biotech
Therapeutic area: Cardiovascular diseases - Metabolic diseases
Type agreement: licensing - development
Action mechanism: protein. ApoC3 is protein with several modes of action: it inhibits very-low-density-lipoproteins (VLDL) uptake by the liver and it inhibits the activity of lipoprotein lipase leading to high levels of lipoproteins and triglycerides. Loss of function mutations in ApoC3 leads to reduced incidence of vascular and heart diseases. This supports the potential of the anti-ApoC3 antibody to act as key molecule in dysplipidemia management.
Disease: dyslipidemia
Details:
- • On January 12, 2015, arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases,announced it has initiated its Innovative Access Program, providing its SIMPLE Antibody™ platform to academic centers of excellence and emerging biotech companies through collaboration. The goal of this program is to exploit the proven power of the SIMPLE Antibody™ platform in therapeutic areas complementary to arGEN-X’s strategic focus.
The first Innovative Access Program collaborations are with an unnamed US-based biotechnology company active in the field of dyslipidemia research and with the de Duve Institute (Université Catholique de Louvain - Belgium) in the field of cancer immunotherapy.
The Innovative Access Program leverages the proven power of the SIMPLE Antibody™ platform in creating best-in-class antibodies across multiple therapeutic areas. Through collaboration with academic centers of excellence and emerging biotech companies, arGEN-X will provide access to its antibody discovery technologies and offer technical support and proprietary know-how where needed. Deal structures are designed to be flexible.
Under the terms of the agreement with the U.S.-based biotech company, arGEN-X will provide access to its suite of antibody discovery technologies and offer technical know-how and expertise. In return, arGEN-X will receive a share in the future commercial success of any asset utilizing the arGEN-X technology. Financial details of the transaction were not disclosed.
Financial terms:
Latest news:
- • On March 6, 2017, argenx announced that Staten Biotech has exercised its exclusive option to license ARGX-116, an anti-ApoC3 SIMPLE antibody with therapeutic potential in dyslipidemia. argenx began its collaboration with Staten Biotech in 2015 as part of a research collaboration through its Innovative Access Program. Under the terms of the agreement, Staten will be responsible for additional development of ARGX-116, and argenx is eligible to receive a double-digit portion on income related to the product. Additional financial details of the collaboration have not been disclosed.
Is general: Yes
